Barclays starts Baxter at Underweight, $20 target
Alpha Vantage · www.marketscreener.com · · AI-summarised by FinFlash
Barclays initiated coverage on Baxter International with an Underweight rating and a $20 price target. The call follows Citigroup's move to trim its Baxter price target to $27 from $28 while keeping a Neutral rating. Baxter, a medical equipment and pharmaceutical company, has also seen recent management changes, including the appointment of John Rogers as Chief Financial Officer. Analyst consensus shows two Buy ratings, eleven Hold ratings and no Sell ratings.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.